Jeffrey Warrington
Instructor in the Rabb School of Continuing Studies, Division of Graduate Professional Studies
Degrees
University of Ottawa, Ph.D.Expertise
organic chemistry, machine learning, artificial intelligence, drug discovery, small molecule, ligand design, organic synthesis, catalysis, molecular modelling, molecular dynamics, computational chemistry, cheminformatics, chemoinformatics, data science, statistics, R, python, knimeProfile
Jeff Warrington, Ph.D. is a senior drug discovery scientist with more than 15 years of experience across multiple areas of areas of small molecule drug research. He was centrally involved in projects that led to the invention of Reldesemtiv (now in Phase II for muscle disorders such as Spinal Muscle Atrophy), and Oxbryta (now approved for Sickle Cell Disease).Dr. Warrington is currently Associate Director of Medicinal chemistry at Ardelyx - a world leader leader in the field of cardiorenal research. There, he actively seeks out cutting edge computational approaches to inform small molecule drug research campaigns. His past experiences include leading drug discovery programs using Artificial Intelligence and machine learning systems at Atomwise.
Dr. Warrington is named in over 30 patents and publications in the field of drug discovery, and has a passion for practical use of in-silico methods to drive forward drug design. He has active collaborations with researchers all over the globe - and is in routine communications with Europe, Asia, and the Americas.
Courses Taught
| RBIF | 110 | Cheminformatics |